Do Cerebral Blood Volume and Contrast Transfer Coefficient Predict Prognosis in Human Glioma?

References

1. ↵
   Wyllie AD. Growth and neoplasia. In: MacSween N, Whaley K. Muir’s textbook of pathology. 13th ed. London: Edward Arnold;1992;355–410
2. ↵
   Plate KH, Breier G, Weich HA, et al., Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845–48

   CrossRefPubMedWeb of Science
3. ↵
   Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol 1995;107:233–35

   CrossRefPubMedWeb of Science
4. ↵
   Chaudhry IH, O’Donovan DG, Brenchley PEC, et al. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 2001;39:409–15

   CrossRefPubMedWeb of Science
5. ↵
   Warmuth C, Gunther M, Zimmer C. Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology 2003;228:523–32

   CrossRefPubMedWeb of Science
6. Sugahara T, Korogi Y, Tomiguchi, et al. Perfusion-sensitive MR imaging of gliomas: comparison between gradient-echo and spin-echo echo-planar imaging techniques. AJNR Am J Neuroradiol 2001;22:1306–15

   Abstract/FREE Full Text
7. Ludemann L, Grieger W, Wurm R, et al. Comparison of dynamic contrast-enhanced MRI with WHO tumor grading for gliomas. Eur Radiol 2001;11:1231–41

   CrossRefPubMed
8. ↵
   Law M, Yang, S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989–98

   Abstract/FREE Full Text
9. Hacklander T, Hofer M, Reichenbach JR, et al. Cerebral blood volume maps with dynamic contrast-enhanced T1-weighted FLASH imaging: normal values and preliminary clinical results. J Comput Assist Tomogr 1996;20:532–39

   CrossRefPubMed
10. Fuss M, Wenz F, Essig M, et al. Tumor angiogenesis of low-grade astrocytomas measured by dynamic susceptibility contrast-enhanced MRI (DSC-MRI) is predictive of local tumor control after radiation therapy. Int J Radiat Oncol Biol Phys 2001;51:478–82

    CrossRefPubMed
11. ↵
    Bruening R, Kwong KK, Vevea MJ, et al. Echo-planar MR determination of relative cerebral blood volume in human brain tumors: T1 versus T2 weighting. AJNR Am J Neuroradiol 1996;17:831–40

    Abstract
12. Aronen HJ, Perkio J. Dynamic susceptibility contrast MRI of gliomas. Neuroimaging Clin North Am 2002;12:501–23
13. ↵
    Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41–51

    PubMedWeb of Science
14. Sugahara T, Korogi Y, Kochi M, et al. Correlation of MR imaging–determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 1998;171:1479–86

    CrossRefPubMedWeb of Science
15. ↵
    Sugahara T, Korogi Y, Shigematsu Y, et al. Value of dynamic susceptibility contrast magnetic resonance imaging in the evaluation of intracranial tumors. Top Magn Reson Imaging 1999;10:114–24

    PubMed
16. ↵
    Wong ET, Jackson ER, Hess KR, et al. Correlation between dynamic MRI and outcome in patients with malignant gliomas. Neurology 1998;50:777–81

    Abstract/FREE Full Text
17. Wong JC, Provenzale JM, Petrella JR. Perfusion MR imaging of brain neoplasms. AJR Am J Roentgenol 2000;174:1147–57

    PubMed
18. Cha S, Knoff EA, Johnson G, et al. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002;223:11–29

    CrossRefPubMedWeb of Science
19. Lev MH, Rosen BR. Clinical applications of intracranial perfusion MR imaging. Neuroimaging Clin North Am 1999;9:309–31
20. ↵
    Petrella JR, Provenzale JM. MR perfusion imaging of the brain: techniques and applications. AJR Am J Roentgenol 2000;175:207–19

    CrossRefPubMedWeb of Science
21. ↵
    Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223–32

    CrossRefPubMedWeb of Science
22. ↵
    Johnson G, Wetzel SG, Cha S, et al. Measuring blood volume and vascular transfer constant from dynamic, T(2)*-weighted contrast-enhanced MRI. Magn Reson Med 2004;51:961–68

    CrossRefPubMed
23. Vonken EP, van Osch MJ, Bakker CJ, et al. Simultaneous quantitative cerebral perfusion and Gd-DTPA extravasation measurement with dual-echo dynamic susceptibility contrast MRI. Magn Reson Med 2000;43:820–27

    CrossRefPubMedWeb of Science
24. ↵
    Zhu XP, Li KL, Kamaly-Asl ID, et al. Quantification of endothelial permeability, leakage space, and blood volume in brain tumors using combined T1 and T2* contrast-enhanced dynamic MR imaging. J Magn Reson Imaging 2000;11:575–85

    CrossRefPubMedWeb of Science
25. ↵
    Li KL, Jackson A. New hybrid technique for accurate and reproducible quantitation of dynamic contrast-enhanced MRI data. Magn Reson Med 2003;50:1286–95

    CrossRefPubMed
26. Roberts TP. Physiologic measurements by contrast-enhanced MR imaging: expectations and limitations. J Magn Reson Imaging 1997;7:82–90

    PubMedWeb of Science
27. ↵
    Weisskoff RM, Boxerman JL, Sorensen AG, et al. Simultaneous blood volume and permeability mapping using a single Gd-based contrast injection. In: Proceedings of the Society of Magnetic Resonance, Second Annual Meeting; 1994 Aug 6–12; San Francisco, Calif. Berkeley, Calif: Society of Magnetic Resonance;1994 :279
28. ↵
    Hacklander T, Reichenbach JR, Modder U. Comparison of cerebral blood volume measurements using the T1 and T2* methods in normal human brains and brain tumors. J Comput Assist Tomogr 1997;21:857–66

    CrossRefPubMed
29. ↵
    Kassner A, Annesley D, Zhu XP, et al. Abnormalities of the contrast re-circulation phase in cerebral tumors demonstrated using dynamic susceptibility contrast-enhanced imaging: a possible marker of vascular tortuosity. J Magn Reson Imaging 2000;11:103–13

    CrossRefPubMed
30. ↵
    Jackson A, Kassner A, Zhu XP, et al. Reproducibility of T2* blood volume and vascular tortuosity maps in cerebral gliomas. J Magn Reson Imaging 2001;14:510–16

    CrossRefPubMed
31. ↵
    Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [published erratum appears in AJNR Am J Neuroradiol 2004;25(3):B1]. AJNR Am J Neuroradiol 2004;25:214–21

    Abstract/FREE Full Text
32. Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999;211:791–98

    CrossRefPubMedWeb of Science
33. ↵
    Shin JH, Lee HK, Kwun BD, et al. Using relative cerebral blood flow and volume to evaluate the histopathologic grade of cerebral gliomas: preliminary results. AJR Am J Roentgenol 2002;179:783–89

    CrossRefPubMed
34. ↵
    Law M, Yang S, Babb JS, et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 2004;25:746–55

    Abstract/FREE Full Text
35. ↵
    Li KL, Jackson A. Simultaneous mapping of blood volume and endothelial permeability surface area product in gliomas using iterative analysis of first-pass dynamic contrast enhanced MRI data. Br J Radiol 2003;76:39–50

    Abstract/FREE Full Text
36. ↵
    Jackson A, Grayson GC, Li KL, et al. Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. Br J Radiol 2003;76:153–62

    Abstract/FREE Full Text
37. ↵
    Provenzale JM, Wang GR, Brenner T, et al. Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol 2002;78:711–16
38. ↵
    Roberts HC, Roberts TPL, Brasch RC, et al. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 2000;21:891–99

    Abstract/FREE Full Text
39. ↵
    Li KL, Zhu XP, Waterton J, et al. Improved 3D quantitative mapping of blood volume and endothelial permeability in brain tumors. J Magn Reson Imaging 2000;12:347–57

    CrossRefPubMed
40. ↵
    Haroon HA, Buckley DL, Patankar TA, et al. A comparison of Ktrans measurements obtained with conventional and first pass pharmacokinetic models in human gliomas. J Magn Reson Imaging 2004;19:527–36

    CrossRefPubMed
41. ↵
    Patankar TA, Haroon HA, Mills SJ, et al. Is volume transfer coefficient (K^trans) related to histological grade in human gliomas? AJNR Am J Neuroradiol 2005;26:2455–65

    Abstract/FREE Full Text
42. ↵
    Bauman G, Lote K, Larson D, et al. Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys 1999;45:923–29

    CrossRefPubMedWeb of Science
43. Scott CB, Scarantino C, Urtasun R, et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90–06. Int J Radiat Oncol Biol Phys 1998;40:51–55

    CrossRefPubMedWeb of Science
44. ↵
    Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002;20:2076–84

    Abstract/FREE Full Text
45. Fazeny-Dorner B, Wenzel C, Veitl M, et al. Survival and prognostic factors of patients with unresectable glioblastoma multiforme. Anticancer Drugs 2003;14:305–12

    PubMed
46. Kreth FW, Berlis A, Spiropoulou V, et al. The role of tumor resection in the treatment of glioblastoma multiforme in adults. Cancer 1999;86:2117–23

    CrossRefPubMedWeb of Science
47. Paszat L, et al. A population-based study of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001;51:100–07

    PubMedWeb of Science
48. ↵
    Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011–18

    CrossRefPubMedWeb of Science
49. ↵
    Kleihues P, Burger PC, Scheithauer, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61:215–25; discussion 226–29

    PubMedWeb of Science
50. ↵
    Collet D. Modeling survival data in medical research. New York: Chapman and Hall;1994